{"id":58626,"date":"2026-03-03T12:49:30","date_gmt":"2026-03-03T04:49:30","guid":{"rendered":"https:\/\/flcube.com\/?p=58626"},"modified":"2026-03-03T12:49:31","modified_gmt":"2026-03-03T04:49:31","slug":"arkbio-partners-with-qilu-pharma-on-azstarys-china-commercialization-adhd-therapy-market-entry","status":"publish","type":"post","link":"https:\/\/flcube.com\/?p=58626","title":{"rendered":"ArkBio Partners with Qilu Pharma on Azstarys China Commercialization \u2013 ADHD Therapy Market Entry"},"content":{"rendered":"\n<p><strong>Shanghai Ark Biopharmaceutical Co., Ltd. (ArkBio)<\/strong> announced a <strong>partnership<\/strong> with <strong>Qilu Pharmaceutical Co., Ltd.<\/strong> to advance the <strong>commercialization of Azstarys<\/strong> (serdexmethylphenidate\/dexmethylphenidate), an <strong>attention\u2011deficit\/hyperactivity disorder (ADHD) therapy<\/strong>, in <strong>Mainland China<\/strong>. Qilu Pharma secures <strong>exclusive commercialization rights<\/strong> while ArkBio retains <strong>Hong Kong, Macau, and Taiwan rights<\/strong> and receives <strong>up to RMB\u202f470\u202fmillion (USD\u202f58\u202fmillion) in milestones plus royalties<\/strong>.<\/p>\n\n\n\n<h2 class=\"wp-block-heading\" id=\"h-transaction-overview\">Transaction Overview<\/h2>\n\n\n\n<figure class=\"wp-block-table\"><table class=\"has-fixed-layout\"><thead><tr><th>Item<\/th><th>Detail<\/th><\/tr><\/thead><tbody><tr><td><strong>Partner 1<\/strong><\/td><td>Shanghai Ark Biopharmaceutical Co., Ltd. (ArkBio)<\/td><\/tr><tr><td><strong>Partner 2<\/strong><\/td><td>Qilu Pharmaceutical Co., Ltd.<\/td><\/tr><tr><td><strong>Product<\/strong><\/td><td>Azstarys (serdexmethylphenidate\/dexmethylphenidate)<\/td><\/tr><tr><td><strong>Indication<\/strong><\/td><td>Attention\u2011deficit\/hyperactivity disorder (ADHD)<\/td><\/tr><tr><td><strong>Territory<\/strong><\/td><td>Mainland China (exclusive to Qilu)<\/td><\/tr><tr><td><strong>Retained Rights<\/strong><\/td><td>ArkBio retains Hong Kong, Macau, Taiwan<\/td><\/tr><tr><td><strong>Milestone Payments<\/strong><\/td><td>Up to <strong>RMB\u202f470\u202fmillion (~\u202fUSD\u202f58\u202fmillion)<\/strong><\/td><\/tr><tr><td><strong>Royalties<\/strong><\/td><td>Based on future net sales<\/td><\/tr><\/tbody><\/table><\/figure>\n\n\n\n<h2 class=\"wp-block-heading\" id=\"h-product-profile-azstarys\">Product Profile \u2013 Azstarys<\/h2>\n\n\n\n<figure class=\"wp-block-table\"><table class=\"has-fixed-layout\"><thead><tr><th>Feature<\/th><th>Detail<\/th><\/tr><\/thead><tbody><tr><td><strong>Components<\/strong><\/td><td>Serdexmethylphenidate (prodrug) + dexmethylphenidate (active)<\/td><\/tr><tr><td><strong>Mechanism<\/strong><\/td><td>CNS stimulant; enhances dopamine and norepinephrine activity<\/td><\/tr><tr><td><strong>Differentiation<\/strong><\/td><td><strong>Dual\u2011release formulation<\/strong> providing both immediate and extended effect<\/td><\/tr><tr><td><strong>Clinical Advantage<\/strong><\/td><td>Single daily dosing; reduced abuse potential via prodrug design<\/td><\/tr><tr><td><strong>Origin<\/strong><\/td><td>Developed by KemPharm (US); approved by FDA in 2021<\/td><\/tr><\/tbody><\/table><\/figure>\n\n\n\n<h2 class=\"wp-block-heading\" id=\"h-strategic-implications\">Strategic Implications<\/h2>\n\n\n\n<ul class=\"wp-block-list\">\n<li><strong>China ADHD Market Opportunity:<\/strong> ADHD affects <strong>~\u202f6\u20118% of Chinese children<\/strong> (~\u202f15\u201120\u202fmillion) with <strong>low diagnosis and treatment rates<\/strong> (~\u202f10% treated); growing awareness and destigmatization drive market expansion.<\/li>\n\n\n\n<li><strong>Qilu Pharma Commercial Strength:<\/strong> Qilu&#8217;s <strong>established hospital and retail pharmacy network<\/strong> provides immediate market access, overcoming ArkBio&#8217;s limited commercial infrastructure.<\/li>\n\n\n\n<li><strong>ArkBio Capital Efficiency:<\/strong> <strong>USD\u202f58\u202fmillion milestone potential<\/strong> plus royalties enables ArkBio to <strong>monetize Azstarys<\/strong> without building domestic sales force, preserving capital for pipeline development.<\/li>\n\n\n\n<li><strong>Prodrug Differentiation:<\/strong> Azstarys&#8217; <strong>serdexmethylphenidate component<\/strong> offers <strong>abuse\u2011deterrent properties<\/strong>\u2014a regulatory and clinical advantage vs. traditional methylphenidate products in a market with growing substance abuse concerns.<\/li>\n<\/ul>\n\n\n\n<h2 class=\"wp-block-heading\" id=\"h-market-context\">Market Context<\/h2>\n\n\n\n<figure class=\"wp-block-table\"><table class=\"has-fixed-layout\"><thead><tr><th>Factor<\/th><th>Impact<\/th><\/tr><\/thead><tbody><tr><td><strong>China ADHD Market Size<\/strong><\/td><td>~\u202f$500\u202fmillion currently; projected <strong>double\u2011digit growth<\/strong> with increased diagnosis and reimbursement expansion<\/td><\/tr><tr><td><strong>Competitive Landscape<\/strong><\/td><td>Methylphenidate (Ritalin, Concerta) and atomoxetine (Strattera) dominate; Azstarys&#8217; prodrug design differentiates from generics<\/td><\/tr><tr><td><strong>Regulatory Environment<\/strong><\/td><td>ADHD stimulants face controlled substance scheduling; abuse\u2011deterrent formulations may receive preferential formulary positioning<\/td><\/tr><tr><td><strong>Greater China Strategy<\/strong><\/td><td>ArkBio retains <strong>HK\/Macau\/Taiwan rights<\/strong> for independent or separate partnership commercialization in higher\u2011margin markets<\/td><\/tr><\/tbody><\/table><\/figure>\n\n\n\n<p><strong>Forward\u2011Looking Statements<\/strong><br>This brief contains forward\u2011looking statements regarding NMPA registration timelines, commercial launch dates, and market penetration for Azstarys in China. Actual results may differ due to risks including regulatory approval delays, competitive generic pricing, and ADHD diagnosis rate growth assumptions.<a href=\"https:\/\/flcube.com\/\">-Fineline Info &amp; Tech<\/a><\/p>\n","protected":false},"excerpt":{"rendered":"<p>Shanghai Ark Biopharmaceutical Co., Ltd. (ArkBio) announced a partnership with Qilu Pharmaceutical Co., Ltd. to&#8230;<\/p>\n","protected":false},"author":1,"featured_media":0,"comment_status":"open","ping_status":"open","sticky":false,"template":"","format":"standard","meta":{"googlesitekit_rrm_CAownpewDA:productID":"","_jetpack_memberships_contains_paid_content":false,"footnotes":"","jetpack_publicize_message":"","jetpack_publicize_feature_enabled":true,"jetpack_social_post_already_shared":true,"jetpack_social_options":{"image_generator_settings":{"template":"highway","default_image_id":0,"font":"","enabled":false},"version":2}},"categories":[7,10],"tags":[1443,208],"class_list":["post-58626","post","type-post","status-publish","format-standard","hentry","category-company","category-deals","tag-ark-biopharmaceutical","tag-qilu-pharmaceutical"],"yoast_head":"<!-- This site is optimized with the Yoast SEO Premium plugin v23.6 (Yoast SEO v27.4) - https:\/\/yoast.com\/product\/yoast-seo-premium-wordpress\/ -->\n<title>ArkBio Partners with Qilu Pharma on Azstarys China Commercialization \u2013 ADHD Therapy Market Entry - Insight, China&#039;s Pharmaceutical Industry<\/title>\n<meta name=\"description\" content=\"Shanghai Ark Biopharmaceutical Co., Ltd. (ArkBio) announced a partnership with Qilu Pharmaceutical Co., Ltd. to advance the commercialization of Azstarys (serdexmethylphenidate\/dexmethylphenidate), an attention\u2011deficit\/hyperactivity disorder (ADHD) therapy, in Mainland China. Qilu Pharma secures exclusive commercialization rights while ArkBio retains Hong Kong, Macau, and Taiwan rights and receives up to RMB\u202f470\u202fmillion (USD\u202f58\u202fmillion) in milestones plus royalties.\" \/>\n<meta name=\"robots\" content=\"index, follow, max-snippet:-1, max-image-preview:large, max-video-preview:-1\" \/>\n<link rel=\"canonical\" href=\"https:\/\/flcube.com\/?p=58626\" \/>\n<meta property=\"og:locale\" content=\"en_US\" \/>\n<meta property=\"og:type\" content=\"article\" \/>\n<meta property=\"og:title\" content=\"ArkBio Partners with Qilu Pharma on Azstarys China Commercialization \u2013 ADHD Therapy Market Entry\" \/>\n<meta property=\"og:description\" content=\"Shanghai Ark Biopharmaceutical Co., Ltd. (ArkBio) announced a partnership with Qilu Pharmaceutical Co., Ltd. to advance the commercialization of Azstarys (serdexmethylphenidate\/dexmethylphenidate), an attention\u2011deficit\/hyperactivity disorder (ADHD) therapy, in Mainland China. Qilu Pharma secures exclusive commercialization rights while ArkBio retains Hong Kong, Macau, and Taiwan rights and receives up to RMB\u202f470\u202fmillion (USD\u202f58\u202fmillion) in milestones plus royalties.\" \/>\n<meta property=\"og:url\" content=\"https:\/\/flcube.com\/?p=58626\" \/>\n<meta property=\"og:site_name\" content=\"Insight, China&#039;s Pharmaceutical Industry\" \/>\n<meta property=\"article:publisher\" content=\"https:\/\/www.facebook.com\/profile.php?id=61566606313834\" \/>\n<meta property=\"article:published_time\" content=\"2026-03-03T04:49:30+00:00\" \/>\n<meta property=\"article:modified_time\" content=\"2026-03-03T04:49:31+00:00\" \/>\n<meta property=\"og:image\" content=\"https:\/\/flcube.com\/wp-content\/uploads\/2024\/11\/Fineline-info-tech-scaled.jpg\" \/>\n\t<meta property=\"og:image:width\" content=\"2560\" \/>\n\t<meta property=\"og:image:height\" content=\"1894\" \/>\n\t<meta property=\"og:image:type\" content=\"image\/jpeg\" \/>\n<meta name=\"author\" content=\"Fineline Cube\" \/>\n<meta name=\"twitter:card\" content=\"summary_large_image\" \/>\n<meta name=\"twitter:description\" content=\"Navigate the complexities of China\u2019s pharmaceutical industry with precision and clarity. FLCUBE delivers reliable data, news, and intelligence to broaden your horizons and sharpen your decision-making. Stay informed, stay ahead with FLCUBE.COM\" \/>\n<meta name=\"twitter:label1\" content=\"Written by\" \/>\n\t<meta name=\"twitter:data1\" content=\"Fineline Cube\" \/>\n\t<meta name=\"twitter:label2\" content=\"Est. reading time\" \/>\n\t<meta name=\"twitter:data2\" content=\"2 minutes\" \/>\n<script type=\"application\/ld+json\" class=\"yoast-schema-graph\">{\"@context\":\"https:\\\/\\\/schema.org\",\"@graph\":[{\"@type\":\"Article\",\"@id\":\"https:\\\/\\\/flcube.com\\\/?p=58626#article\",\"isPartOf\":{\"@id\":\"https:\\\/\\\/flcube.com\\\/?p=58626\"},\"author\":{\"name\":\"Fineline Cube\",\"@id\":\"https:\\\/\\\/flcube.com\\\/#\\\/schema\\\/person\\\/19ad11870d326204db8524d3c3c5e66a\"},\"headline\":\"ArkBio Partners with Qilu Pharma on Azstarys China Commercialization \u2013 ADHD Therapy Market Entry\",\"datePublished\":\"2026-03-03T04:49:30+00:00\",\"dateModified\":\"2026-03-03T04:49:31+00:00\",\"mainEntityOfPage\":{\"@id\":\"https:\\\/\\\/flcube.com\\\/?p=58626\"},\"wordCount\":389,\"commentCount\":0,\"publisher\":{\"@id\":\"https:\\\/\\\/flcube.com\\\/#organization\"},\"keywords\":[\"Ark Biopharmaceutical\",\"Qilu Pharmaceutical\"],\"articleSection\":[\"Company\",\"Deals\"],\"inLanguage\":\"en-US\",\"potentialAction\":[{\"@type\":\"CommentAction\",\"name\":\"Comment\",\"target\":[\"https:\\\/\\\/flcube.com\\\/?p=58626#respond\"]}],\"copyrightYear\":\"2026\",\"copyrightHolder\":{\"@id\":\"https:\\\/\\\/flcube.com\\\/#organization\"}},{\"@type\":\"WebPage\",\"@id\":\"https:\\\/\\\/flcube.com\\\/?p=58626\",\"url\":\"https:\\\/\\\/flcube.com\\\/?p=58626\",\"name\":\"ArkBio Partners with Qilu Pharma on Azstarys China Commercialization \u2013 ADHD Therapy Market Entry - Insight, China&#039;s Pharmaceutical Industry\",\"isPartOf\":{\"@id\":\"https:\\\/\\\/flcube.com\\\/#website\"},\"datePublished\":\"2026-03-03T04:49:30+00:00\",\"dateModified\":\"2026-03-03T04:49:31+00:00\",\"description\":\"Shanghai Ark Biopharmaceutical Co., Ltd. (ArkBio) announced a partnership with Qilu Pharmaceutical Co., Ltd. to advance the commercialization of Azstarys (serdexmethylphenidate\\\/dexmethylphenidate), an attention\u2011deficit\\\/hyperactivity disorder (ADHD) therapy, in Mainland China. Qilu Pharma secures exclusive commercialization rights while ArkBio retains Hong Kong, Macau, and Taiwan rights and receives up to RMB\u202f470\u202fmillion (USD\u202f58\u202fmillion) in milestones plus royalties.\",\"breadcrumb\":{\"@id\":\"https:\\\/\\\/flcube.com\\\/?p=58626#breadcrumb\"},\"inLanguage\":\"en-US\",\"potentialAction\":[{\"@type\":\"ReadAction\",\"target\":[\"https:\\\/\\\/flcube.com\\\/?p=58626\"]}]},{\"@type\":\"BreadcrumbList\",\"@id\":\"https:\\\/\\\/flcube.com\\\/?p=58626#breadcrumb\",\"itemListElement\":[{\"@type\":\"ListItem\",\"position\":1,\"name\":\"Home\",\"item\":\"https:\\\/\\\/flcube.com\\\/\"},{\"@type\":\"ListItem\",\"position\":2,\"name\":\"ArkBio Partners with Qilu Pharma on Azstarys China Commercialization \u2013 ADHD Therapy Market Entry\"}]},{\"@type\":\"WebSite\",\"@id\":\"https:\\\/\\\/flcube.com\\\/#website\",\"url\":\"https:\\\/\\\/flcube.com\\\/\",\"name\":\"Insight, China's Pharmaceutical Industry\",\"description\":\"Fineline Insights, Pharma Clarity\",\"publisher\":{\"@id\":\"https:\\\/\\\/flcube.com\\\/#organization\"},\"potentialAction\":[{\"@type\":\"SearchAction\",\"target\":{\"@type\":\"EntryPoint\",\"urlTemplate\":\"https:\\\/\\\/flcube.com\\\/?s={search_term_string}\"},\"query-input\":{\"@type\":\"PropertyValueSpecification\",\"valueRequired\":true,\"valueName\":\"search_term_string\"}}],\"inLanguage\":\"en-US\"},{\"@type\":\"Organization\",\"@id\":\"https:\\\/\\\/flcube.com\\\/#organization\",\"name\":\"Fineline Infomation and Technology\",\"alternateName\":\"Fineline Info & Tech\",\"url\":\"https:\\\/\\\/flcube.com\\\/\",\"logo\":{\"@type\":\"ImageObject\",\"inLanguage\":\"en-US\",\"@id\":\"https:\\\/\\\/flcube.com\\\/#\\\/schema\\\/logo\\\/image\\\/\",\"url\":\"https:\\\/\\\/flcube.com\\\/wp-content\\\/uploads\\\/2024\\\/11\\\/Fineline-info-tech-scaled.jpg\",\"contentUrl\":\"https:\\\/\\\/flcube.com\\\/wp-content\\\/uploads\\\/2024\\\/11\\\/Fineline-info-tech-scaled.jpg\",\"width\":2560,\"height\":1894,\"caption\":\"Fineline Infomation and Technology\"},\"image\":{\"@id\":\"https:\\\/\\\/flcube.com\\\/#\\\/schema\\\/logo\\\/image\\\/\"},\"sameAs\":[\"https:\\\/\\\/www.facebook.com\\\/profile.php?id=61566606313834\"]},{\"@type\":\"Person\",\"@id\":\"https:\\\/\\\/flcube.com\\\/#\\\/schema\\\/person\\\/19ad11870d326204db8524d3c3c5e66a\",\"name\":\"Fineline Cube\",\"image\":{\"@type\":\"ImageObject\",\"inLanguage\":\"en-US\",\"@id\":\"https:\\\/\\\/secure.gravatar.com\\\/avatar\\\/89f733aaed3d2d91d7d6f45d0e9ab509e3004e8243c6e57620b36380684657f2?s=96&d=mm&r=g\",\"url\":\"https:\\\/\\\/secure.gravatar.com\\\/avatar\\\/89f733aaed3d2d91d7d6f45d0e9ab509e3004e8243c6e57620b36380684657f2?s=96&d=mm&r=g\",\"contentUrl\":\"https:\\\/\\\/secure.gravatar.com\\\/avatar\\\/89f733aaed3d2d91d7d6f45d0e9ab509e3004e8243c6e57620b36380684657f2?s=96&d=mm&r=g\",\"caption\":\"Fineline Cube\"},\"sameAs\":[\"https:\\\/\\\/flcube.com\"],\"url\":\"https:\\\/\\\/flcube.com\\\/?author=1\"}]}<\/script>\n<!-- \/ Yoast SEO Premium plugin. -->","yoast_head_json":{"title":"ArkBio Partners with Qilu Pharma on Azstarys China Commercialization \u2013 ADHD Therapy Market Entry - Insight, China&#039;s Pharmaceutical Industry","description":"Shanghai Ark Biopharmaceutical Co., Ltd. (ArkBio) announced a partnership with Qilu Pharmaceutical Co., Ltd. to advance the commercialization of Azstarys (serdexmethylphenidate\/dexmethylphenidate), an attention\u2011deficit\/hyperactivity disorder (ADHD) therapy, in Mainland China. Qilu Pharma secures exclusive commercialization rights while ArkBio retains Hong Kong, Macau, and Taiwan rights and receives up to RMB\u202f470\u202fmillion (USD\u202f58\u202fmillion) in milestones plus royalties.","robots":{"index":"index","follow":"follow","max-snippet":"max-snippet:-1","max-image-preview":"max-image-preview:large","max-video-preview":"max-video-preview:-1"},"canonical":"https:\/\/flcube.com\/?p=58626","og_locale":"en_US","og_type":"article","og_title":"ArkBio Partners with Qilu Pharma on Azstarys China Commercialization \u2013 ADHD Therapy Market Entry","og_description":"Shanghai Ark Biopharmaceutical Co., Ltd. (ArkBio) announced a partnership with Qilu Pharmaceutical Co., Ltd. to advance the commercialization of Azstarys (serdexmethylphenidate\/dexmethylphenidate), an attention\u2011deficit\/hyperactivity disorder (ADHD) therapy, in Mainland China. Qilu Pharma secures exclusive commercialization rights while ArkBio retains Hong Kong, Macau, and Taiwan rights and receives up to RMB\u202f470\u202fmillion (USD\u202f58\u202fmillion) in milestones plus royalties.","og_url":"https:\/\/flcube.com\/?p=58626","og_site_name":"Insight, China&#039;s Pharmaceutical Industry","article_publisher":"https:\/\/www.facebook.com\/profile.php?id=61566606313834","article_published_time":"2026-03-03T04:49:30+00:00","article_modified_time":"2026-03-03T04:49:31+00:00","og_image":[{"width":2560,"height":1894,"url":"https:\/\/flcube.com\/wp-content\/uploads\/2024\/11\/Fineline-info-tech-scaled.jpg","type":"image\/jpeg"}],"author":"Fineline Cube","twitter_card":"summary_large_image","twitter_description":"Navigate the complexities of China\u2019s pharmaceutical industry with precision and clarity. FLCUBE delivers reliable data, news, and intelligence to broaden your horizons and sharpen your decision-making. Stay informed, stay ahead with FLCUBE.COM","twitter_misc":{"Written by":"Fineline Cube","Est. reading time":"2 minutes"},"schema":{"@context":"https:\/\/schema.org","@graph":[{"@type":"Article","@id":"https:\/\/flcube.com\/?p=58626#article","isPartOf":{"@id":"https:\/\/flcube.com\/?p=58626"},"author":{"name":"Fineline Cube","@id":"https:\/\/flcube.com\/#\/schema\/person\/19ad11870d326204db8524d3c3c5e66a"},"headline":"ArkBio Partners with Qilu Pharma on Azstarys China Commercialization \u2013 ADHD Therapy Market Entry","datePublished":"2026-03-03T04:49:30+00:00","dateModified":"2026-03-03T04:49:31+00:00","mainEntityOfPage":{"@id":"https:\/\/flcube.com\/?p=58626"},"wordCount":389,"commentCount":0,"publisher":{"@id":"https:\/\/flcube.com\/#organization"},"keywords":["Ark Biopharmaceutical","Qilu Pharmaceutical"],"articleSection":["Company","Deals"],"inLanguage":"en-US","potentialAction":[{"@type":"CommentAction","name":"Comment","target":["https:\/\/flcube.com\/?p=58626#respond"]}],"copyrightYear":"2026","copyrightHolder":{"@id":"https:\/\/flcube.com\/#organization"}},{"@type":"WebPage","@id":"https:\/\/flcube.com\/?p=58626","url":"https:\/\/flcube.com\/?p=58626","name":"ArkBio Partners with Qilu Pharma on Azstarys China Commercialization \u2013 ADHD Therapy Market Entry - Insight, China&#039;s Pharmaceutical Industry","isPartOf":{"@id":"https:\/\/flcube.com\/#website"},"datePublished":"2026-03-03T04:49:30+00:00","dateModified":"2026-03-03T04:49:31+00:00","description":"Shanghai Ark Biopharmaceutical Co., Ltd. (ArkBio) announced a partnership with Qilu Pharmaceutical Co., Ltd. to advance the commercialization of Azstarys (serdexmethylphenidate\/dexmethylphenidate), an attention\u2011deficit\/hyperactivity disorder (ADHD) therapy, in Mainland China. Qilu Pharma secures exclusive commercialization rights while ArkBio retains Hong Kong, Macau, and Taiwan rights and receives up to RMB\u202f470\u202fmillion (USD\u202f58\u202fmillion) in milestones plus royalties.","breadcrumb":{"@id":"https:\/\/flcube.com\/?p=58626#breadcrumb"},"inLanguage":"en-US","potentialAction":[{"@type":"ReadAction","target":["https:\/\/flcube.com\/?p=58626"]}]},{"@type":"BreadcrumbList","@id":"https:\/\/flcube.com\/?p=58626#breadcrumb","itemListElement":[{"@type":"ListItem","position":1,"name":"Home","item":"https:\/\/flcube.com\/"},{"@type":"ListItem","position":2,"name":"ArkBio Partners with Qilu Pharma on Azstarys China Commercialization \u2013 ADHD Therapy Market Entry"}]},{"@type":"WebSite","@id":"https:\/\/flcube.com\/#website","url":"https:\/\/flcube.com\/","name":"Insight, China's Pharmaceutical Industry","description":"Fineline Insights, Pharma Clarity","publisher":{"@id":"https:\/\/flcube.com\/#organization"},"potentialAction":[{"@type":"SearchAction","target":{"@type":"EntryPoint","urlTemplate":"https:\/\/flcube.com\/?s={search_term_string}"},"query-input":{"@type":"PropertyValueSpecification","valueRequired":true,"valueName":"search_term_string"}}],"inLanguage":"en-US"},{"@type":"Organization","@id":"https:\/\/flcube.com\/#organization","name":"Fineline Infomation and Technology","alternateName":"Fineline Info & Tech","url":"https:\/\/flcube.com\/","logo":{"@type":"ImageObject","inLanguage":"en-US","@id":"https:\/\/flcube.com\/#\/schema\/logo\/image\/","url":"https:\/\/flcube.com\/wp-content\/uploads\/2024\/11\/Fineline-info-tech-scaled.jpg","contentUrl":"https:\/\/flcube.com\/wp-content\/uploads\/2024\/11\/Fineline-info-tech-scaled.jpg","width":2560,"height":1894,"caption":"Fineline Infomation and Technology"},"image":{"@id":"https:\/\/flcube.com\/#\/schema\/logo\/image\/"},"sameAs":["https:\/\/www.facebook.com\/profile.php?id=61566606313834"]},{"@type":"Person","@id":"https:\/\/flcube.com\/#\/schema\/person\/19ad11870d326204db8524d3c3c5e66a","name":"Fineline Cube","image":{"@type":"ImageObject","inLanguage":"en-US","@id":"https:\/\/secure.gravatar.com\/avatar\/89f733aaed3d2d91d7d6f45d0e9ab509e3004e8243c6e57620b36380684657f2?s=96&d=mm&r=g","url":"https:\/\/secure.gravatar.com\/avatar\/89f733aaed3d2d91d7d6f45d0e9ab509e3004e8243c6e57620b36380684657f2?s=96&d=mm&r=g","contentUrl":"https:\/\/secure.gravatar.com\/avatar\/89f733aaed3d2d91d7d6f45d0e9ab509e3004e8243c6e57620b36380684657f2?s=96&d=mm&r=g","caption":"Fineline Cube"},"sameAs":["https:\/\/flcube.com"],"url":"https:\/\/flcube.com\/?author=1"}]}},"jetpack_publicize_connections":[],"jetpack_featured_media_url":"","jetpack_sharing_enabled":true,"_links":{"self":[{"href":"https:\/\/flcube.com\/index.php?rest_route=\/wp\/v2\/posts\/58626","targetHints":{"allow":["GET"]}}],"collection":[{"href":"https:\/\/flcube.com\/index.php?rest_route=\/wp\/v2\/posts"}],"about":[{"href":"https:\/\/flcube.com\/index.php?rest_route=\/wp\/v2\/types\/post"}],"author":[{"embeddable":true,"href":"https:\/\/flcube.com\/index.php?rest_route=\/wp\/v2\/users\/1"}],"replies":[{"embeddable":true,"href":"https:\/\/flcube.com\/index.php?rest_route=%2Fwp%2Fv2%2Fcomments&post=58626"}],"version-history":[{"count":1,"href":"https:\/\/flcube.com\/index.php?rest_route=\/wp\/v2\/posts\/58626\/revisions"}],"predecessor-version":[{"id":58627,"href":"https:\/\/flcube.com\/index.php?rest_route=\/wp\/v2\/posts\/58626\/revisions\/58627"}],"wp:attachment":[{"href":"https:\/\/flcube.com\/index.php?rest_route=%2Fwp%2Fv2%2Fmedia&parent=58626"}],"wp:term":[{"taxonomy":"category","embeddable":true,"href":"https:\/\/flcube.com\/index.php?rest_route=%2Fwp%2Fv2%2Fcategories&post=58626"},{"taxonomy":"post_tag","embeddable":true,"href":"https:\/\/flcube.com\/index.php?rest_route=%2Fwp%2Fv2%2Ftags&post=58626"}],"curies":[{"name":"wp","href":"https:\/\/api.w.org\/{rel}","templated":true}]}}